Boceprevir; Cobicistat; Telaprevir/CYP3A4 Inducers Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Apalutamide, carbamazepine, enzalutamide, fosphenytoin, lumacaftor, natisedine, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, rifampin, and St. John's wort may speed up how quickly your liver processes boceprevir, cobicistat, and telaprevir.
What might happen:
The amount of boceprevir or telaprevir in your blood may decrease and it may not work as well against your hepatitis.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have taken apalutamide, carbamazepine, enzalutamide, fosphenytoin, lumacaftor, natisedine, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifapentine, rifampin, or St. John's wort in the previous two weeks, or if you stop taking St. John's wort. Your doctor may want to adjust your medicines.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Victrelis (boceprevir) US prescribing information. Schering Corporation January, 2017.
- 2.Tybost (cobicistat) EMA summary of product characteristics. Gilead Sciences Limited May, 2014.
- 3.Incivek (telaprevir) US prescribing information. Vertex Pharmaceuticals Incorporated October, 2013.
- 4.Viramune (nevirapine) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. March, 2017.
- 5.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
- 6.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
- 7.Tybost (cobicistat) US prescribing information. Gilead Sciences, Inc. October, 2018.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.